1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Justin Ryder: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD | Phase 2 | Not yet recruiting | Justin Ryder | 40 | 2027-05-01 | 2026-01-20 |
| Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease | Phase 2 | Recruiting | Justin Ryder | 40 | 2025-04-10 | 2026-01-21 |
Non-alcoholic Fatty Liver Disease (2)
Control Groups (2) · empagliflozin (2)
United States (2)